Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Concept art showing a money icon and human hands

Funding

China’s Corxel Nabs $287M Series D1 to Bankroll GLP-1 Pill

Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.

January 23, 2026

1 min read

Tristan Manalac

Vaccines

Moderna Won’t Run Phase III Vaccine Trials as Skepticism Grows in US: Bloomberg

Growing opposition to vaccines in the U.S., driven by recent government policy changes, makes it difficult to see a return on investment in vaccine development, Moderna CEO Stéphane Bancel said this week.

January 23, 2026

2 min read

Tristan Manalac

2006 James Gathany Captured by James Gathany, Centers for Disease Control's biomedical photographer, this 2006 image depicted the exterior of the new "Tom Harkin Global Communications Center", otherwise known as Building 19, located on the organization's Roybal Campus in Atlanta, Georgia. The facility houses the CDC's Information Center/Library, auditoria and meeting halls, which are used to accommodate in-house staff meetings, and national/international conferences hosted by the CDC, and the National Center for Health Marketing's, Division of Creative Services, which includes a full service television broadcast facility. The exhibit area currently features the "Global Symphony", the first of several permanently installed exhibitions, and changing exhibitions that focus on a variety of public health topics. The exhibits in the Center are self-guided, and require no advance reservations. Additional curriculum-based exhibits and programming will be added in the future. Tom Harkin Global Communications Center Exhibit Area Centers for Disease Control and Prevention - 1600 Clifton Road, N.E., Atlanta, Georgia 30333 - Hours: Monday Friday, 9 am 5 pm, except for federal holidays Admission is free - Government-issue photo ID is required for entry. Please note that CDC is a working federal facility and as such does not provide public tours of its campus and laboratories. - For more information please call 404-639-0830.

Vaccines

ACIP Chair Questions Polio Vaccines, Values Individual Choice Over Public Benefit

“I don’t like established science,” ACIP chairperson Kirk Milhoan said in an interview on the Why Should I Trust You? podcast. “Science is what I observe.”

January 23, 2026

2 min read

Tristan Manalac

Pictured: Bristol Myers Squibb office in California

Cancer

BMS Bets $850M on Janux’s Tumor-Activated Drugs, Deepening Cancer Investments

The partnership will allow BMS to advance a T cell–based therapy that is only activated once in the vicinity of a tumor.

January 22, 2026

2 min read

Tristan Manalac

Business and Project Roadmap Concept. Touching on virtual screen with roadmap overlay representing steps in a project or strategic planning process. Waypoint icons and ends with goal achievement.

Manufacturing

FDA Sets Feb. 1 Launch Date for PreCheck Pilot To Strengthen Domestic Supply Chain

The U.S. regulator shared the roadmap for implementing the program, first proposed in August 2025, and teased changes made in response to industry feedback.

January 22, 2026

2 min read

Nick Paul Taylor

Start early or business advantage. Businessman starts running ahead of competitors vector

Pain

Lexicon Opens Path to $1B+ Opportunity as FDA Greenlights Phase III for Non-Opioid Pill

The company also stands to gain from recent regulatory FDA guidance aimed at streamlining the development of non-opioid painkillers, Jefferies analysts suggested.

January 22, 2026

2 min read

Tristan Manalac

Vaccines

‘Almost Like a Religion’: Pfizer CEO Slams RFK Jr.’s ‘Anti-Science’ Vaccine Policies

Pfizer CEO Albert Bourla said that the main thing getting in the way of changing vaccine discussions in the U.S. is the Secretary of Health, Robert F. Kennedy, Jr.

January 22, 2026

2 min read

Tristan Manalac

Insights

From Sound Bites to Signals: Editors Parse Executive and Investor Chatter at JPM

In this episode of Denatured, BioSpace editorial team members, Senior Editor, Annalee Armstrong, and News Editor, Dan Samorodnitsky, discuss their post-JPM takeaways and 2026 forecasts after speaking to a range of pharma and biotech executives and investors last week.

January 22, 2026

1 min read

Jennifer C. Smith-Parker

MRI or magnetic resonance imaging of the head and brain. Close up

Insights

The New Gold Rush in Brain Science

Fueled by advances in biomarkers, brain mapping, and AI, investment in neuro and CNS innovation shows no signs of slowing, even amid costly setbacks. BioSpace spoke to investors at JPM26 to get their take on recent bets in new therapies and neurotech.

January 22, 2026

5 min read

Jennifer C. Smith-Parker

Visit website

Email Us

IN THE PRESS

Press Releases

Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer

June 2, 2025

4 min read

BioMidwest

Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings